Blog

Jan 11, 2025, 10:05

Rémy Duléry: T cell malignancies after CAR T cell therapy in the DESCAR-T registry

Rémy Duléry, Professor of Hematology at Sorbonne University, Saint-Antoine Hospital in Paris, shared on X:

“Happy to share our work published in Nature Medicine

We analyzed 3,066 patients from the French DESCAR-T registry who received CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%).”

T cell malignancies after CAR T cell therapy in the DESCAR-T registry | Nature Medicine

Authors: Remy Dulery, Vincent Guiraud, Sylvain Choquet, Catherine Thieblemont, Emmanuel Bachy, Stéphane Barete, Ève Todesco, Bertrand Arnulf, Nicolas Boissel, André Baruchel, Jacques-Olivier Bay, Steven Le Gouill and Roch Houot.

Rémy Duléry: T cell malignancies after CAR T cell therapy in the DESCAR-T registry

André Baruchel Bertrand Arnulf cancer Catherine Thieblemont Emmanuel Bachy Ève Todesco Jacques-Olivier Bay Nicolas Boissel OncoDaily Oncology Rémy Duléry Stéphane Barete Steven Le Gouill and Roch Houot Sylvain Choquet Vincent Guiraud

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term

Do Artificial Sweeteners Cause Cancer? Myths and Facts